期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

77例青年晚期肺腺癌ERCC-1、p53蛋白表达与含顺铂方案化疗疗效关系 被引量：1

Relationship between Expression of ERCC-1, p53 and Efficacy of Cisplatin Based Regimen in 77 Cases with Advanced Adolescent Adenocarcinoma of Lung
原文传递
导出
摘要 [目的]分析青年晚期肺腺癌患者组织中错配切除修复蛋白(ERCC-1)、p53表达与含顺铂方案化疗疗效和生存之间的关系。[方法]收集1997年1月～2005年12月采用含顺铂方案治疗的病理确诊为晚期肺腺癌82例患者的蜡块。采用免疫组化的方法检测ERCC-1、p53的表达,并与含顺铂方案治疗的疗效和生存进行比较。[结果]共有77例可以评价染色,ERCC-1阳性率为33.77%,p53阳性率为53.25%。ERCC-1阳性表达患者顺铂化疗有效率低,并且TTP和PFS较短,p53阳性表达患者生存较差。[结论]ERCC-1阳性表达与青年晚期肺腺癌含顺铂方案化疗耐药相关,p53表达提示青年晚期肺腺癌患者不良预后。
作者 陈小兵 罗素霞 卢超霞
机构地区 郑州大学第一附属医院 河南省肿瘤医院 中国医学科学院中国协和医科大学基础医学研究所
出处 《中国肿瘤》 CAS 2008年第12期1070-1072,共3页 China Cancer
基金 河南省科技创新人才工程项目(2002479)
关键词 肺肿瘤 腺癌 青年人 错配切除修复蛋白 p53 顺铂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

二级参考文献43

  • 1[1]SeidegardJ, Pero RW, Markowitz MM, et al. Isoenzyme(s) of glutathione transferase(class Mu) as a marker for the susceptibility to lung cancer. A follow up study [J]. Carcinogenesis, 1990, 11 (1):33 ～36
  • 2[2]London SJ, Yuan JM, Chung FL, et al. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lungcancer risk: A prospective study of men in Shanghai, China [J].The Lancet, 2000, 356(9231): 724～729
  • 3[3]Benhamou S, Lee WJ, Alexandrie AK, et al. Meta-and pooled analyses of the effects of glutathione S-transferase M1 plymorphisms and smoking on lung cancer risk[J]. Carcinogenesis, 2002,23(8): 1343～1350
  • 4[4]Stucker I, Hirvonen A, Waziers I, et al. Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility[J]. Carcinogenesis, 2002, 23(9): 1475～1481
  • 5[5]Ahrendt SA, Chow JT, Yang SC, et al. Alcohol consumption and cigarette smoking increase the frequency of P53 mutations in not- small cell lung cancer [J]. Cancer Res, 2000, 60(12): 3155～3159
  • 6[6]Husgafvel PK,Boffetta P, Kannio A, et al. P53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer[J]. Cancer Res, 2000, 60(11): 2906～2911
  • 7[7]Saeki H, Ohno S, Araki K, et al. Alcohol consumption and cigarette smoking in relation to high frequency of P53 protein accumulation in oesophageal squamous cell carcinoma in the Japanese[J]. Br J Cancer, 2000, 82(11): 1892～ 1894
  • 8[8]McLellan RA, Oscarson M, Alexandrie AK, et al. Characterization of a Human Glutathione S-Transferase μ Cluster Containing a Duplicated GSTM1 Gene that Causes Ultrarapid Enzyme Activity Roman[J]. Mol Pharmacol, 1997, 52( 6): 958～965
  • 9[9]Kim JW, Lee CG, Park YG, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, and CYP2E1: relation to the incidence rate of cervical carcinoma[J]. Cancer, 2000, 88(9):2082～2091
  • 10[10]Raunio H, Husgafvel PK, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review[J]. Gene, 1995, 159(1): 113～121

共引文献46

同被引文献17

  • 1宋德刚,王哲海.DNA修复基因预测非小细胞肺癌化疗敏感性研究进展[J].实用癌症杂志,2006,21(5):540-541. 被引量：1
  • 2陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
  • 3Ceppi P,Vovello S. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advenced non-small-cell lung cancer treated with cisplatin and gemcitabine[J].Annals of Oncology,2006,(12):1818.
  • 4Lord RV,Brabender J,Gandara D. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer[J].Clinical Cancer Research,2002,(07):2286.
  • 5In Gyu Hwang,Myung Ju Ahn. ERCC1 Expression as a prognostic marker in N2(1) non-small-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy[J].Cancer,2008,(06):1380.
  • 6Zhou W,Liu G,Park S. Gene smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[J].Cancer Epidemiology Biomarkers & Prevention,2005,(02):491.
  • 7Wachters FM,Wong LS,Timens W. ERCC1 hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy[J].Lung Cancer,2005,(02):211.
  • 8Olaussen KA,Dunant A,Fouret P. DNA repair by ERCC1 in non-small lung cancer and cisplatin-based adjuvant chemotherapy[J].New England Journal of Medicine,2006,(10):983.
  • 9Yang LY,Li L,Jing H. Expression of cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair[J].Clinical Cancer Research,2000.773.
  • 10Rose PG. Gemcitabine reverse platinum resistance in platnum-resistant ovarian and peritoneal carcinoma[J].International Journal of Gynecological Cancer,2005,(Suppl 1):18.

引证文献1

二级引证文献3

中国肿瘤
2008年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部